Clinical Trial Update: Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing nateglinide versus acarbose in adults with type 2 diabetes assessing postprandial glucose fluctuations, dyslipidemia, and infla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Precose (acarbose)
• Starlix (nateglinide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2011-07-07